Computational Evaluation of Substituted 2-Aminopyrimidine Schiff Bases as Potential Antidepressant Targeting the Muscarinic Acetylcholine M5 Receptor
DOI:
https://doi.org/10.63682/jns.v14i2S.7230Keywords:
2-Aminopyrimidine, Schiff base derivatives, Muscarinic M5 receptor, Antidepressant activity, Molecular docking, FluoxetineAbstract
The effectiveness of existing treatments for depression, a complicated mental health condition that affects people all over the world, is limited. The ability of the muscarinic acetylcholine receptor subtype M5 (M5 mAChR) to modulate dopaminergic and cholinergic pathways has made it a unique target in the search for antidepressant drugs. This work used molecular docking to assess the antidepressant potential of fifteen newly created substituted 2-Aminopyrimidine Schiff base derivatives that target the M5 receptor. For the docking simulations, Auto Dock Tools version 1.5.7 was utilized, and the reference antidepressant was fluoxetine. Out of the fifteen compounds, the four derivatives with the highest binding affinities were SSS-14, SSS-13, SSS-01, and SSS-11. In the ortho steric binding pocket of the M5 receptor, these chemicals showed persistent connections with important amino acid residues through hydrophobic contacts, π–π stacking, and hydrogen bonding. The chosen derivatives’ structural characteristics allowed for favourable receptor interaction and spatial orientation. Based on the results, substituted 2-Aminopyrimidine Schiff bases have the potential to be effective antidepressants by selectively modulating the M5 receptor. This study offers a useful computational basis for lead optimization and additional pharmacological validation in the creation of innovative antidepressant treatments
Downloads
Metrics
References
World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: WHO; 2017.
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-66.
Eglen RM, Vickers CA. Muscarinic receptor subtypes in the central nervous system. Handb Exp Pharmacol. 2012;208:33-54.
Kumar A, Jaitak V. Therapeutic potential of pyrimidine derivatives: a patent review (2010–2018). Expert Opin Ther Pat. 2019;29(6):461-77.
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785-91.
PerkinElmer Inc. ChemDraw Professional. Version 19.0; 2018.
ACD/Labs. ChemSketch. Version 2020.2.0; 2020.
Schrödinger, LLC. PyMOL Molecular Graphics System. Version 2.0; 2015.
O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform. 2011;3:33.
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785-91.
Nickel J, Gohlke BO, Erehman J, Banerjee P, Rong W-W, Goede A, et al. SuperPred: update on drug classification and target prediction. Nucleic Acids Res. 2014;42(W1):W26-31.
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235-42.
BIOVIA Dassault Systèmes. Discovery Studio Visualizer. Version 2020; 2020.
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26.
Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257-63.
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615-23.
Daina A, Zoete V. A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem. 2016;11(11):1117–1121.
Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, et al. admetSAR: a comprehensive source and free tool for assessing chemical ADMET properties. J Chem Inf Model. 2012;52(11):3099–3105.
Pires DE, Blundell TL, Ascher DB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem. 2015;58(9):4066–4072.
Wu S, Liu H, Zhang J, Wei J, Chen L, Gao W, et al. Advancements in in silico toxicity prediction: From machine learning to deep learning. Front Pharmacol. 2020;11:580101.
Raies AB, Bajic VB. In silico toxicology: computational methods for the prediction of chemical toxicity. Wiley Interdiscip Rev Comput Mol Sci. 2016;6(2):147-172.
Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek GJ. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 2002;7 Suppl 1:S71-80.
Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci. 2009;30(3):148-155.
Basile AS, Wess J. Muscarinic receptor subtypes and CNS function. Neuropharmacology. 2002;43(4):451-460
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
